Abstract
Phenomena that occur between an insulin and four different positively charged polymers (protamine, cationic dextran, chitosan, and poliallylamine derivatives) were studied by dynamic light scattering and fluorescence measurements (using fluorescein-labeled polymers). These processes were compared to the reaction of polycations with heparin that is responsible for the neutralization of anticoagulant activity in blood stream.The nature of polycations interaction with heparin is electrostatic, while the interaction with insulin is more complicated.We observed that the presence of zinc atoms (and its complexing by nitrogen from macromolecules) is critical for insulin suspensions formation and stability. The differences between the nature of these two reactions were revealed. The highly immunogenic action of protamine present in long-acting insulin products makes it reasonable to develop similar systems based on the nonprotein polycations.
Ethical Approval: The conducted research is not related to either human or animal use.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Conflict of interests: The authors declare no conflict of interest.
References
[1] Urwin N, Whiting D, Guariguata L, Ghyoot G, Gan D, editors. International Diabetes Federation’s 5th ed. of the Diabetes Atlas, Brussels, 14 November -World Diabetes Day, 2011.Search in Google Scholar
[2] Rother KI. Diabetes treatment – bridging the divide. N Engl J Med 2007;356:1499–501.10.1056/NEJMp078030Search in Google Scholar
[3] Hirsch IB. Treatment of patients with severe insulin deficiency: what we have learned over the past 2 years. Am J Med 2004;116:17–22.10.1016/j.amjmed.2003.12.005Search in Google Scholar
[4] Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002;16:475–92.10.1053/bega.2002.0321Search in Google Scholar
[5] Baganz HM, Carfagno SC, Cowan BY, Dillon ES. NPH insulin; its comparison with previous insulin regimens. Am Med Sci 1951;2:22.10.1097/00000441-195107000-00001Search in Google Scholar
[6] Burnham DK. Insulin and insulin mixtures; NPH insulin. Calif Med 1951;75:412–5.Search in Google Scholar
[7] Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thrombosis Res 1999;94:53–61.10.1016/S0049-3848(98)00201-1Search in Google Scholar
[8] Ando T, Yamsaki M, Suzuki K. Protamines. Isolation, characterisation, structure and function. Mol Biol Biochem Biophys 1973;12:1–109.10.1007/978-3-642-46294-8_1Search in Google Scholar
[9] Chu YQ, Cai LJ, Jiang DC, Jia D, Yan SY, Wang YQ. Allergic shock and death associated with protamine administration in a diabetic patient. Clin Therapeut 2010;32:1729–32.10.1016/j.clinthera.2010.09.010Search in Google Scholar
[10] Nell LJ and Thomas JW. Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes 1988;37:172–6.10.2337/diab.37.2.172Search in Google Scholar
[11] Baur X, Bossert J, Koops F. IgE-mediated allergy to recombinant human insulin in a diabetic. Allergy 2003;58:676–8.10.1034/j.1398-9995.2003.00128.xSearch in Google Scholar
[12] Aris A, Solanes H, Bonnin JO, Garin R, Caralps JM. Intraaortic administration of protamine: method for heparin neutralization after cardiopulmonary bypass. Cardiovasc Dis 1981;8:23–8.Search in Google Scholar
[13] Panos A, Orrit X, Chevalley C, Kalangos A. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur Cardio-thoracic Surg 2003;24:325–7.10.1016/S1010-7940(03)00252-5Search in Google Scholar
[14] Mclaughlin KE, Dunning J. In patients post cardiac surgery do high doses of protamine cause increased bleeding? Interactive Cardiovascular Thoracic Surg 2003:2:424–6.10.1016/S1569-9293(03)00200-7Search in Google Scholar
[15] Gale AJ, Elias DJ, Averell PM, Teirstein PS, Buck M, Brown SD, et al. Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients. Thrombosis Res 2011;128:9–13.10.1016/j.thromres.2011.03.021Search in Google Scholar
[16] Kamiński K, Szczubiałka K, Zazakowny K, Lach R, Nowakowska M. Chitosan derivatives as novel potential heparin reversal agents. J Med Chem 2010;53:4141–7.10.1021/jm1001666Search in Google Scholar
[17] Kamiński K, Płonka M, Ciejka J, Szczubiałka K, Nowakowska M, Lorkowska B, et al. Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists. J Med Chem 2011;54:6586–96.10.1021/jm200380wSearch in Google Scholar
[18] Kim JJ and Park K. Modulated insulin delivery from glucose-sensitive hydrogel dosage forms. J Controlled Release 2001;77:39–47.10.1016/S0168-3659(01)00447-3Search in Google Scholar
[19] Merisko-Liversidge E, McGurk SL, Liversidge GG. Insulin nanoparticles: anovel formulation approach for poorly water soluble Zn-insulin. Pharmaceut Res 2004;21:1545–53.10.1023/B:PHAM.0000041446.14569.e2Search in Google Scholar
[20] Sarmento B, Ferreira D, Veiga F, Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym 2006;66:1–7.10.1016/j.carbpol.2006.02.008Search in Google Scholar
[21] Samal SK, Dash M, Van Vlierberghe S, Kaplan DL, Chiellini E, van Blitterswijk C, et al. Cationic polymers and their therapeutic potential. Chem Soc Rev 2012;41:7147–94.10.1039/c2cs35094gSearch in Google Scholar PubMed
[22] Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalinska K, et al. Nonclinical evaluation of vovel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS One 2015;10:e0119486.10.1371/journal.pone.0119486Search in Google Scholar PubMed PubMed Central
[23] Kalaska B, Kaminski K, Miklosz J, Yusa SI, Sokolowska E, Blazejczyk A, et al. Heparin-binding copolymer (HBC) reverses effects of unfractionated heparin, enoxaparin and fondaparinux in rats and mice. Transl Res 2016;177:98–112.10.1016/j.trsl.2016.06.009Search in Google Scholar PubMed
[24] Kamiński K, Kałaska B, Koczurkiewicz P, Michalik M, Szczubiałka K, Mogielnicki A, et al. New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. Med Chem Commun 2014;5:489–95.10.1039/c3md00374dSearch in Google Scholar
[25] Gok E, Olgaz S. Binding of fluorescein isothiocyanate to insulin: afluorimetric labeling study. Fluorescence 2004;14:2.10.1023/B:JOFL.0000016292.00622.25Search in Google Scholar
[26] He1 H, David AE, Zhang J, Park YS, Wang J, Huang Y, et al. Low molecular weight protamine/insulin formulation with potential to attenuate protamine-masqueraded insulin allergy. Macromol Res 2011;19:1224–6.10.1007/s13233-011-1214-0Search in Google Scholar
[27] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–5.10.1038/227680a0Search in Google Scholar PubMed
[28] Graham PA, Nash AS, McKellar QA. Pharmacokinetics of a porcine insulin zinc suspension in diabetic dogs. J Small Animal Practice 1997;38:434–8.10.1111/j.1748-5827.1997.tb03435.xSearch in Google Scholar PubMed
[29] Norrmana M, Hubaleka F, Schluckebier G. Structural characterization of insulin NPH formulations. Eur J Pharmaceut Sci 2007;30:414–23.10.1016/j.ejps.2007.01.003Search in Google Scholar PubMed
© 2019 Walter de Gruyter GmbH, Berlin/Boston
